Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT06951087
PHASE3

Intravitreal and Intracameral DEX in NPDR

Sponsor: Affiliated Hospital of Nantong University

View on ClinicalTrials.gov

Summary

To investigate the effects of intravitreal and intracameral injection of dexamethasone during cataract phacoemulsification in patients with mild to moderate non-proliferative diabetic retinopathy

Official title: Effect of Intravitreal and Intracameral Injection of Dexamethasone Sodium Phosphate on Mild to Moderate NPDR During Cataract Phacoemulsification

Key Details

Gender

All

Age Range

Any - Any

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2022-01-31

Completion Date

2025-06-01

Last Updated

2025-04-30

Healthy Volunteers

No

Interventions

DRUG

Dexamethasone sodium phosphate

In patients with stable DR and no significant macular edema, intravitreal anti-VEGF injections after phacoemulsification surgery can prevent the worsening of postoperative macular edema and potentially improve final visual outcomes while maintaining safety. Laser coagulation and intravitreal anti-VEGF injections are currently considered the standard treatments for PDR. However, the cost of anti-VEGF drugs often prevents many patients from receiving regular and timely injections. Intravitreal corticosteroids may be used as an alternative to anti-VEGF agents.

Locations (1)

Eye Institute, Affiliated Hospital of Nantong University

Nantong, Jiangsu, China